In these trials, which selected patients based on tumor PD-L1 expression status, the anti-PD-1 antibody showed superior survival outcomes compared to platinum-based chemotherapy, and subsequently, the anti-PD-L1 antibody atezolizumab also demonstrated overall superiority over platinum-based chemotherapy (3, 43) (Figures 1A, B; Supplementary Table 1). This evidence concerns the gene CD274 and neoplasm.